Abbott (ABT) Stock
Global healthcare company making medical devices and nutrition. Here's the price, business snapshot, and what's worth knowing about Abbott in October 2026.
Abbott Laboratories (ABT) is a diversified global healthcare company operating across diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. With a market capitalisation around $221.98B, Abbott supplies a mix of recurring-revenue products — from diagnostic systems and cardiovascular devices to glucose-monitoring products and infant nutrition — that can offer relative resilience across economic cycles. Investors should note its exposure to regulatory approvals, reimbursement policies and competition from large medtech and pharmaceutical peers, plus currency and supply-chain risks in international markets. Abbott invests in R&D and product upgrades, which can support long-term growth but also requires ongoing capital. The company has historically returned cash to shareholders, yet past distributions do not guarantee future payments. This summary is for general, educational purposes and is not personalised investment advice; individuals should assess suitability, consult up-to-date sources, and consider seeking regulated financial advice before investing.
Why It’s Moving
Abbott Stock Swings on Mixed Q3 Results and Major Nutrition Spin-Off Announcement
- The company announced a tax-free spin-off of its nutrition segment into an independent publicly traded company, a move analysts project could increase Abbott's growth rate by 50–100 basis points and expand gross margins by 200 basis points.
- Third-quarter adjusted EPS came in at $1.42, slightly missing the consensus estimate of $1.43, while reported sales rose 14.5% year-over-year to $13.01 billion, fueled significantly by the Exact Sciences acquisition in diagnostics.
- Management reduced the full-year 2026 sales growth outlook due to challenges in diabetes pricing and electrophysiology, even as they reaffirmed adjusted EPS guidance of $5.50–$5.55 and highlighted new product approvals including the Oncodetect MRD test.
Abbott Stock Swings on Mixed Q3 Results and Major Nutrition Spin-Off Announcement
- The company announced a tax-free spin-off of its nutrition segment into an independent publicly traded company, a move analysts project could increase Abbott's growth rate by 50–100 basis points and expand gross margins by 200 basis points.
- Third-quarter adjusted EPS came in at $1.42, slightly missing the consensus estimate of $1.43, while reported sales rose 14.5% year-over-year to $13.01 billion, fueled significantly by the Exact Sciences acquisition in diagnostics.
- Management reduced the full-year 2026 sales growth outlook due to challenges in diabetes pricing and electrophysiology, even as they reaffirmed adjusted EPS guidance of $5.50–$5.55 and highlighted new product approvals including the Oncodetect MRD test.
Sixth Month Growth Performance
When is the next earnings date for Abbott (ABT)?
ABT has not yet announced a confirmed date for its next earnings report. Based on the historical reporting pattern of quarterly releases, the upcoming announcement is expected in January 2027. This report will cover the fourth quarter of fiscal year 2026. Investors should monitor company communications for the official scheduling of this release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Abbott's stock with a target price of $124.84, indicating good growth potential.
Financial Health
Abbott is performing well, showing strong profits, cash flow, and revenue in recent months.
Dividend
Abbott's dividend yield of 2.4% is moderate and provides some income for investors. If you invested $1000 you would be paid $24 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Stable revenue mix
Recurring sales from diagnostics and devices can support steadier cash flows, though performance will vary and is not guaranteed.
Global market reach
A broad international footprint offers growth opportunities but brings currency, regulatory and supply-chain exposure to watch.
Product innovation focus
Ongoing R&D and device upgrades can drive long-term growth, yet new product development faces regulatory and competitive hurdles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
